Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2012, Article ID 872091, 11 pages
http://dx.doi.org/10.1155/2012/872091
Review Article

Implications of Therapy-Induced Selective Autophagy on Tumor Metabolism and Survival

1Deeley Research Centre, BC Cancer Agency, 2410 Lee Avenue, Victoria, BC, Canada V8R 6V5
2Department of Biochemistry and Microbiology, University of Victoria, Petch Bldg, Ring Road, Victoria, BC, Canada V8P 5C2

Received 16 November 2011; Accepted 14 January 2012

Academic Editor: Masaaki Komatsu

Copyright © 2012 Luke R. K. Hughson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar
  2. B. Bonavida, “Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions,” Oncogene, vol. 26, no. 25, pp. 3629–3636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Giocanti, C. Hennequin, J. Balosso, M. Mahler, and V. Favaudon, “DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide,” Cancer Research, vol. 53, no. 9, pp. 2105–2111, 1993. View at Google Scholar · View at Scopus
  4. P. G. Richardson, B. Barlogie, J. Berenson et al., “A phase 2 study of Bortezomib in relapsed, refractory myeloma,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2609–2617, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. L. Simons, I. M. Ahmad, D. M. Mattson, K. J. Dornfeld, and D. R. Spitz, “2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells,” Cancer Research, vol. 67, no. 7, pp. 3364–3370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Spiegelman, R. Sawyer, and R. Nayak, “Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 8, pp. 4966–4970, 1980. View at Google Scholar · View at Scopus
  7. R. A. Cairns, I. Papandreou, P. D. Sutphin, and N. C. Denko, “Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 22, pp. 9445–9450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Hernlund, L. S. Ihrlund, O. Khan et al., “Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir,” International Journal of Cancer, vol. 123, no. 2, pp. 476–483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. B. K. Mohanti, G. K. Rath, N. Anantha et al., “Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas,” International Journal of Radiation Oncology Biology Physics, vol. 35, no. 1, pp. 103–111, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. L. M. DeAngelis, V. E. Currie, J. H. Kim et al., “The combined use of radiation therapy and lonidamine in the treatment of brain metastases,” Journal of Neuro-Oncology, vol. 7, no. 3, pp. 241–247, 1989. View at Google Scholar · View at Scopus
  11. S. P. Elmore, T. Qian, S. F. Grissom, and J. J. Lemasters, “The mitochondrial permeability transition initiates autophagy in rat hepatocytes,” The FASEB Journal, vol. 15, no. 12, pp. 2286–2287, 2001. View at Google Scholar · View at Scopus
  12. Y. E. Park, Y. K. Hayashi, G. Bonne et al., “Autophagic degradation of nuclear components in mammalian cells,” Autophagy, vol. 5, no. 6, pp. 795–804, 2009. View at Google Scholar · View at Scopus
  13. S. Pankiv, T. H. Clausen, T. Lamark et al., “p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy,” The Journal of Biological Chemistry, vol. 282, no. 33, pp. 24131–24145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Klionsky, E. H. Baehrecke, J. H. Brumell et al., “A comprehensive glossary of autophagy-related molecules and processes (2nd edition),” Autophagy, vol. 7, no. 11, pp. 1273–1294, 2011. View at Publisher · View at Google Scholar
  15. C. H. Jung, C. B. Jun, S. H. Ro et al., “ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery,” Molecular Biology of the Cell, vol. 20, no. 7, pp. 1992–2003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. I. G. Ganley, D. H. Lam, J. Wang, X. Ding, S. Chen, and X. Jiang, “ULK1·ATG13·FIP200 complex mediates mTOR signaling and is essential for autophagy,” The Journal of Biological Chemistry, vol. 284, no. 18, pp. 12297–12305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Hanada, N. N. Noda, Y. Satomi et al., “The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy,” The Journal of Biological Chemistry, vol. 282, no. 52, pp. 37298–37302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Itakura, C. Kishi, K. Inoue, and N. Mizushima, “Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG,” Molecular Biology of the Cell, vol. 19, no. 12, pp. 5360–5372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Mizushima, T. Noda, T. Yoshimori et al., “A protein conjugation system essential for autophagy,” Nature, vol. 395, no. 6700, pp. 395–398, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Mizushima, H. Sugita, T. Yoshimori, and Y. Ohsumi, “A new protein conjugation system in human: the counterpart of the yeast Apg12p conjugation system essential for autophagy,” The Journal of Biological Chemistry, vol. 273, no. 51, pp. 33889–33892, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. S. Sou, S. Waguri, J. I. Iwata et al., “The Atg8 conjugation system is indispensable for proper development of autophagic isolation membranes in mice,” Molecular Biology of the Cell, vol. 19, no. 11, pp. 4762–4775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. R. J. Young, E. Y. W. Chan, X. W. Hu et al., “Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes,” Journal of Cell Science, vol. 119, no. 18, pp. 3888–3900, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Mizushima, T. Yoshimori, and Y. Ohsumi, “The role of atg proteins in autophagosome formation,” Annual Review of Cell and Developmental Biology, vol. 27, pp. 107–132, 2011. View at Publisher · View at Google Scholar
  24. H. Weidberg, E. Shvets, and Z. Elazar, “Biogenesis and cargo selectivity of autophagosomes,” Annual Review of Biochemistry, vol. 80, pp. 125–156, 2011. View at Publisher · View at Google Scholar
  25. A. U. Arstila, J. D. Shelburne, and B. F. Trump, “Studies on cellular autophagocytosis. A histochemical study on sequential alterations of mitochondria in the glucagon-induced autophagic vacuoles of rat liver,” Laboratory Investigation, vol. 27, no. 3, pp. 317–323, 1972. View at Google Scholar · View at Scopus
  26. I. Kim, S. Rodriguez-Enriquez, and J. J. Lemasters, “Selective degradation of mitochondria by mitophagy,” Archives of Biochemistry and Biophysics, vol. 462, no. 2, pp. 245–253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Matsuda, S. Sato, K. Shiba et al., “PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy,” Journal of Cell Biology, vol. 189, no. 2, pp. 211–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Geisler, K. M. Holmström, D. Skujat et al., “PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1,” Nature Cell Biology, vol. 12, no. 2, pp. 119–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Ikeda and T. K. Kerppola, “Lysosomal localization of ubiquitinated jun requires multiple determinants in a lysine-27-linked polyubiquitin conjugate,” Molecular Biology of the Cell, vol. 19, no. 11, pp. 4588–4601, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. J. M. M. Tan, E. S. P. Wong, D. S. Kirkpatrick et al., “Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases,” Human Molecular Genetics, vol. 17, no. 3, pp. 431–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Peng, D. Schwartz, J. E. Elias et al., “A proteomics approach to understanding protein ubiquitination,” Nature Biotechnology, vol. 21, no. 8, pp. 921–926, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Hicke, H. L. Schubert, and C. P. Hill, “Ubiquitin-binding domains,” Nature Reviews Molecular Cell Biology, vol. 6, no. 8, pp. 610–621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. L. Seibenhener, J. R. Babu, T. Geetha, H. C. Wong, N. R. Krishna, and M. W. Wooten, “Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation,” Molecular and Cellular Biology, vol. 24, no. 18, pp. 8055–8068, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Shvets, A. Abada, H. Weidberg, and Z. Elazar, “Dissecting the involvement of LC3B and GATE-16 in p62 recruitment into autophagosomes,” Autophagy, vol. 7, no. 7, pp. 683–688, 2011. View at Publisher · View at Google Scholar
  35. N. Fujita, M. Hayashi-Nishino, H. Fukumoto et al., “An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in autophagosome closure,” Molecular Biology of the Cell, vol. 19, no. 11, pp. 4651–4659, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. D. P. Narendra, L. A. Kane, D. N. Hauser, I. M. Fearnley, and R. J. Youle, “p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both,” Autophagy, vol. 6, no. 8, pp. 1090–1106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Okatsu, K. Saisho, M. Shimanuki et al., “P62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria,” Genes to Cells, vol. 15, no. 8, pp. 887–900, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. W. X. Ding, H. M. Ni, M. Li et al., “Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming,” The Journal of Biological Chemistry, vol. 285, no. 36, pp. 27879–27890, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Rodríguez-Hernández, M. D. Cordero, L. Salviati et al., “Coenzyme Q deficiency triggers mitochondria degradation by mitophagy,” Autophagy, vol. 5, no. 1, pp. 19–32, 2009. View at Google Scholar · View at Scopus
  40. C. van Humbeeck, T. Cornelissen, H. Hofkens et al., “Parkin interacts with ambra1 to induce mitophagy,” Journal of Neuroscience, vol. 31, no. 28, pp. 10249–10261, 2011. View at Publisher · View at Google Scholar
  41. D. Narendra, A. Tanaka, D. F. Suen, and R. J. Youle, “Parkin is recruited selectively to impaired mitochondria and promotes their autophagy,” Journal of Cell Biology, vol. 183, no. 5, pp. 795–803, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Ligeret, S. Barthélémy, G. B. Doulakas et al., “Fluoride curcumin derivatives: new mitochondrial uncoupling agents,” FEBS Letters, vol. 569, no. 1–3, pp. 37–42, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Galluzzi, N. Larochette, N. Zamzami, and G. Kroemer, “Mitochondria as therapeutic targets for cancer chemotherapy,” Oncogene, vol. 25, no. 34, pp. 4812–4830, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. F. L. Graham and G. F. Whitmore, “The effect of-beta-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells,” Cancer Research, vol. 30, no. 11, pp. 2627–2635, 1970. View at Google Scholar · View at Scopus
  45. A. Inagaki, T. Nakamura, and G. Wakisaka, “Studies on the mechanism of action of 1-beta-D-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes,” Cancer Research, vol. 29, no. 12, pp. 2169–2176, 1969. View at Google Scholar · View at Scopus
  46. D. Decaudin, S. Geley, T. Hirsch et al., “Bcl-2 and Bcl-X(L) antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents,” Cancer Research, vol. 57, no. 1, pp. 62–67, 1997. View at Google Scholar · View at Scopus
  47. M. S. Blumenreich, T. C. Chou, and M. Andreeff, “Thymidine as a kinetic and biochemical modulator of 1-β-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia,” Cancer Research, vol. 44, no. 2, pp. 825–830, 1984. View at Google Scholar · View at Scopus
  48. A. P. Early, H. D. Preisler, H. Slocum, and Y. M. Rustum, “A pilot study of high-dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology,” Cancer Research, vol. 42, no. 4, pp. 1587–1594, 1982. View at Google Scholar · View at Scopus
  49. G. Jan, A. S. Belzacq, D. Haouzi et al., “Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria,” Cell Death and Differentiation, vol. 9, no. 2, pp. 179–188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Tang, Y. Chen, H. Jiang, and D. Nie, “Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death,” Cell Death and Differentiation, vol. 18, pp. 602–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. A. Miller, E. Kurschel, R. Osieka, and C. G. Schmidt, “Clinical pharmacology of sodium butyrate in patients with acute leukemia,” European Journal of Cancer and Clinical Oncology, vol. 23, no. 9, pp. 1283–1287, 1987. View at Google Scholar · View at Scopus
  52. I. C. Henderson, J. C. Allegra, T. Woodcock et al., “Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 7, no. 5, pp. 560–571, 1989. View at Google Scholar · View at Scopus
  53. R. H. Wheeler, W. D. Ensminger, J. H. Thrall, and J. L. Anderson, “High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia,” Cancer Treatment Reports, vol. 66, no. 3, pp. 493–498, 1982. View at Google Scholar · View at Scopus
  54. S. Kobayashi, P. Volden, D. Timm, K. Mao, X. Xu, and Q. Liang, “Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death,” The Journal of Biological Chemistry, vol. 285, no. 1, pp. 793–804, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Osheroff, “Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide,” Biochemistry, vol. 28, no. 15, pp. 6157–6160, 1989. View at Google Scholar · View at Scopus
  56. D. Kelsen, O. T. Atiq, L. Saltz et al., “FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer,” Journal of Clinical Oncology, vol. 10, no. 4, pp. 541–548, 1992. View at Google Scholar · View at Scopus
  57. S. R. Evans, S. E. Krown, M. A. Testa, T. P. Cooley, and J. H. Von Roenn, “Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study,” Journal of Clinical Oncology, vol. 20, no. 15, pp. 3236–3241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Mavroudis, E. Papadakis, M. Veslemes et al., “A multicenter randomized clinical trial comparing paclitaxel-cisplatin- etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer,” Annals of Oncology, vol. 12, no. 4, pp. 463–470, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Katayama, T. Kawaguchi, M. S. Berger, and R. O. Pieper, “DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells,” Cell Death and Differentiation, vol. 14, no. 3, pp. 548–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Pelicano, D. S. Martin, R. H. Xu, and P. Huang, “Glycolysis inhibition for anticancer treatment,” Oncogene, vol. 25, no. 34, pp. 4633–4646, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Ravagnan, I. Marzo, P. Costantini et al., “Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore,” Oncogene, vol. 18, no. 16, pp. 2537–2546, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. B. H. Long and C. R. Fairchild, “Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase,” Cancer Research, vol. 54, no. 16, pp. 4355–4361, 1994. View at Google Scholar · View at Scopus
  63. J. F. Kidd, M. F. Pilkington, M. J. Schell et al., “Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore,” The Journal of Biological Chemistry, vol. 277, no. 8, pp. 6504–6510, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” The New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. R. Hitt, A. López-Pousa, J. Martínez-Trufero et al., “Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8636–8645, 2005. View at Publisher · View at Google Scholar
  66. L. Welles, M. W. Seville, J. Lietzau et al., “Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma,” Journal of Clinical Oncology, vol. 16, no. 3, pp. 1112–1121, 1998. View at Google Scholar
  67. R. S. Herbst, D. Prager, R. Hermann et al., “TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5892–5899, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. A. du Bois, H. J. Lück, W. Meier et al., “A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer,” Journal of the National Cancer Institute, vol. 95, no. 17, pp. 1320–1330, 2003. View at Google Scholar · View at Scopus
  69. G. Xi, X. Hu, B. Wu et al., “Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells,” Cancer Letters, vol. 307, no. 2, pp. 141–148, 2011. View at Publisher · View at Google Scholar
  70. M. Carré, N. André, G. Carles et al., “Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 33664–33669, 2002. View at Publisher · View at Google Scholar
  71. A. Romero, M. G. Rabinovich, C. T. Vallejo et al., “Vinorelbine as first-line chemotherapy for metastatic breast carcinoma,” Journal of Clinical Oncology, vol. 12, no. 2, pp. 336–341, 1994. View at Google Scholar · View at Scopus
  72. F. V. Fossella, R. DeVore, R. N. Kerr et al., “Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens,” Journal of Clinical Oncology, vol. 18, no. 12, pp. 2354–2362, 2000. View at Google Scholar
  73. X. Fu, Y. Pan, J. Wang, Q. Liu, G. Yang, and J. Li, “The role of autophagy in human lung cancer cell line A549 induced by Vinorelbine,” Chinese Journal of Lung Cancer, vol. 11, no. 3, pp. 345–348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. R. P. Hertzberg, M. J. Caranfa, and S. M. Hecht, “On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex,” Biochemistry, vol. 28, no. 11, pp. 4629–4638, 1989. View at Google Scholar · View at Scopus
  75. Y. Shimada, M. Yoshino, A. Wakui et al., “Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 11, no. 5, pp. 909–913, 1993. View at Google Scholar
  76. N. Masuda, M. Fukuoka, Y. Kusunoki et al., “CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer,” Journal of Clinical Oncology, vol. 10, no. 8, pp. 1225–1229, 1992. View at Google Scholar · View at Scopus
  77. D. J. T. Wagener, H. E. R. Verdonk, L. Y. Dirix et al., “Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study,” Annals of Oncology, vol. 6, no. 2, pp. 129–132, 1995. View at Google Scholar · View at Scopus
  78. H. Bae and J. L. Guan, “Suppression of autophagy by FIP200 deletion impairs DNA damage repair and increases cell death upon treatments with anticancer agents,” Molecular Cancer Research, vol. 9, no. 9, pp. 1232–1241, 2011. View at Publisher · View at Google Scholar
  79. M. A. Fuertes, J. Castilla, C. Alonso, and J. M. Pérez, “Cisplatin biochemical mechanism of action: from cytotoxity to induction of cell death through interconnections between apoptotic and necrotic pathways,” Current Medicinal Chemistry, vol. 10, no. 3, pp. 257–266, 2003. View at Google Scholar · View at Scopus
  80. D. Liu, Y. Yang, Q. Liu, and J. Wang, “Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells,” Medical Oncology, vol. 28, no. 1, pp. 105–111, 2011. View at Publisher · View at Google Scholar
  81. M. Milani, T. Rzymski, H. R. Mellor et al., “The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib,” Cancer Research, vol. 69, no. 10, pp. 4415–4423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. W. X. Ding, H. M. Ni, W. Gao et al., “Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability,” American Journal of Pathology, vol. 171, no. 2, pp. 513–524, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. W. X. Ding, H. M. Ni, W. Gao et al., “Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy,” Molecular Cancer Therapeutics, vol. 8, no. 7, pp. 2036–2045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. R. I. Fisher, S. H. Bernstein, B. S. Kahl et al., “Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma,” Journal of Clinical Oncology, vol. 24, no. 30, pp. 4867–4874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. P. G. Richardson, P. Sonneveld, M. W. Schuster et al., “Bortezomib or high-dose dexamethasone for relapsed multiple myeloma,” The New England Journal of Medicine, vol. 352, no. 24, pp. 2487–2498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Zhu, K. Dunner, and D. J. McConkey, “Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells,” Oncogene, vol. 29, no. 3, pp. 451–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Ruiz, Y. Krupnik, M. Keating, J. Chandra, M. Palladino, and D. McConkey, “The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia,” Molecular Cancer Therapeutics, vol. 5, no. 7, pp. 1836–1843, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. D. Chauhan, A. Singh, M. Brahmandam et al., “Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma,” Blood, vol. 111, no. 3, pp. 1654–1664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Colell, J. E. Ricci, S. Tait et al., “GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation,” Cell, vol. 129, no. 5, pp. 983–997, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956. View at Google Scholar · View at Scopus
  91. O. Warburg, F. Wind, and E. Negelein, “The metabolism of tumors in the body,” The Journal of General Physiology, vol. 8, pp. 519–530, 1927. View at Google Scholar
  92. L. Milane, Z. Duan, and M. Amiji, “Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer,” PLoS ONE, vol. 6, no. 9, article e24075, 2011. View at Publisher · View at Google Scholar
  93. A. Floridi, T. Bruno, S. Miccadei, M. Fanciulli, A. Federico, and M. G. Paggi, “Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant ehrlich ascites tumor cells through modulation of energy metabolism,” Biochemical Pharmacology, vol. 56, no. 7, pp. 841–849, 1998. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Mijaljica, M. Prescott, and R. J. Devenish, “The intricacy of nuclear membrane dynamics during nucleophagy,” Nucleus, vol. 1, no. 3, pp. 213–223, 2010. View at Google Scholar · View at Scopus
  95. A. L. Kovács, G. Réz, Z. Pálfia, and J. Kovács, “Autophagy in the epithelial cells of murine seminal vesicle in vitro: formation of large sheets of nascent isolation membranes, sequestration of the nucleus and inhibition by wortmannin and 3-methyladenine,” Cell and Tissue Research, vol. 302, no. 2, pp. 253–261, 2000. View at Google Scholar · View at Scopus
  96. K. H. Sit, R. Paramanantham, B. H. Bay et al., “Sequestration of mitotic (M-phase) chromosomes in autophagosomes: mitotic programmed cell death in human Chang liver cells induced by an OH* burst from vanadyl(4),” Anatomical Record, vol. 245, no. 1, pp. 1–8, 1996. View at Publisher · View at Google Scholar · View at Scopus
  97. K. H. Sit, R. Paramanantham, B. H. Bay, K. P. Wong, P. Thong, and F. Watt, “Induction of vanadium accumulation and nuclear sequestration causing cell suicide in human Chang liver cells,” Experientia, vol. 52, no. 8, pp. 778–784, 1996. View at Google Scholar · View at Scopus
  98. R. Dawaliby and A. Mayer, “Microautophagy of the nucleus coincides with a vacuolar diffusion barrier at nuclear-vacuolar junctions,” Molecular Biology of the Cell, vol. 21, no. 23, pp. 4173–4183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Roberts, S. Moshitch-Moshkovitz, E. Kvam, E. O'Toole, M. Winey, and D. S. Goldfarb, “Piecemeal microautophagy of nucleus in Saccharomyces cerevisiae,” Molecular Biology of the Cell, vol. 14, no. 1, pp. 129–141, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. R. Krick, Y. Muehe, T. Prick et al., “Piecemeal microautophagy of the nucleus requires the core macroautophagy genes,” Molecular Biology of the Cell, vol. 19, no. 10, pp. 4492–4505, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. W. H. de Vos, F. Houben, R. A. Hoebe et al., “Increased plasticity of the nuclear envelope and hypermobility of telomeres due to the loss of A-type lamins,” Biochimica et Biophysica Acta, vol. 1800, no. 4, pp. 448–458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. S. H. Kaufmann, “Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note,” Cancer Research, vol. 49, no. 21, pp. 5870–5878, 1989. View at Google Scholar · View at Scopus
  103. T. Akematsu, R. E. Pearlman, and H. Endoh, “Gigantic macroautophagy in programmed nuclear death of Tetrahymena thermophila,” Autophagy, vol. 6, no. 7, pp. 901–911, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Swietach, R. D. Vaughan-Jones, and A. L. Harris, “Regulation of tumor pH and the role of carbonic anhydrase 9,” Cancer and Metastasis Reviews, vol. 26, no. 2, pp. 299–310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Wittig and J. F. Coy, “The role of glucose metabolism and glucose-associated signalling in cancer,” Perspectives in Medicinal Chemistry, vol. 1, pp. 64–82, 2008. View at Google Scholar
  106. R. Shashidharamurthy, H. A. Koteiche, J. Dong, and H. S. Mchaourab, “Mechanism of chaperone function in small heat shock proteins: dissociation of the HSP27 oligomer is required for recognition and binding of destabilized T4 lysozyme,” The Journal of Biological Chemistry, vol. 280, no. 7, pp. 5281–5289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Murata, Y. Minami, M. Minami, T. Chiba, and K. Tanaka, “CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein,” EMBO Reports, vol. 2, no. 12, pp. 1133–1138, 2001. View at Publisher · View at Google Scholar · View at Scopus
  108. S. B. Jänen, H. Chaachouay, and C. Richter-Landsberg, “Autophagy is activated by proteasomal inhibition and involved in aggresome clearance in cultured astrocytes,” Glia, vol. 58, no. 14, pp. 1766–1774, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. U. B. Pandey, Z. Nie, Y. Batlevi et al., “HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS,” Nature, vol. 447, no. 7146, pp. 859–863, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Iwata, B. E. Riley, J. A. Johnston, and R. R. Kopito, “HDAC6 and microtubules are required for autophagic degradation of aggregated Huntingtin,” The Journal of Biological Chemistry, vol. 280, no. 48, pp. 40282–40292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. J. A. Olzmann, A. Li, M. V. Chudaev et al., “Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6,” Journal of Cell Biology, vol. 178, no. 6, pp. 1025–1038, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. D. J. Moore, “Parkin: a multifaceted ubiquitin ligase,” Biochemical Society Transactions, vol. 34, no. 5, pp. 749–753, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. K. M. A. Rouschop, T. van den Beucken, L. Dubois et al., “The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 127–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Grant, “Enhancing proteotoxic stress as an anticancer strategy,” Oncotarget, vol. 2, no. 4, pp. 284–286, 2011. View at Google Scholar
  115. C. M. Haynes, E. A. Titus, and A. A. Cooper, “Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death,” Molecular Cell, vol. 15, no. 5, pp. 767–776, 2004. View at Publisher · View at Google Scholar · View at Scopus
  116. R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth, “Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer,” Clinical Cancer Research, vol. 13, no. 4, pp. 1208–1215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. A. M. Davies, K. Chansky, P. N. Lara Jr. et al., “Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II southwest oncology group study (S0339),” Journal of Thoracic Oncology, vol. 4, no. 1, pp. 87–92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Kraft, M. Peter, and K. Hofmann, “Selective autophagy: ubiquitin-mediated recognition and beyond,” Nature Cell Biology, vol. 12, no. 9, pp. 836–841, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Matsumoto, H. Yasui, J. B. Mitchell, and M. C. Krishna, “Imaging cycling tumor hypoxia,” Cancer Research, vol. 70, no. 24, pp. 10019–10023, 2010. View at Publisher · View at Google Scholar · View at Scopus